IMPACT PM
The IMPACT-PM platform (Integrative Metabolomics for Translational and Precision Medicine) was established within UMR 1283 INSERM / 8199 CNRS EGENODIA to provide dedicated metabolomics services and complement the human genomics expertise of the LIGAN-PM platform (labeled IBISA).
The mission of the IMPACT-PM platform is to provide comprehensive characterization of the metabolome across various biomedical contexts. To do so, we apply high-throughput, high-resolution mass spectrometry workflows to support our analysis. This approach ensures broad coverage and accurate annotation of a wide range of metabolites, including those related to endogenous metabolism, the microbiome, and various exposures such as nutritional, pharmaceutical, and chemical.
Our expertise includes:
-
Global metabolomics: In-depth profiling for a comprehensive overview of metabolites.
-
Targeted metabolomics: isotopic quantification of metabolites of interest.
-
High-confidence annotations: based on our internal library of over 2,800 pure standards.
-
Analysis of various biological samples: plasma, serum, urine, tissues, etc.
-
Computational metabolomics: Advanced chemometric and bioinformatic analyses.
Why contacting IMPACT-PM for your metabolomics needs?
We combine technological innovation with a highly skilled team specializing in advanced analytical chemistry and data science approaches, supporting biomedical research projects. Our platform is supported by the CHU de Lille, CNRS, Inserm, Institut Pasteur de Lille, and the University of Lille and is funded by:
- The Accueil de Talent 2020 grant from Isite ULNE.
- Co-funding from LABEX EGID (European Genomic Institute for Diabetes Research Federation) under the Investments for the Future Program (PIA).
- A workpackage from IHU-B Precidiab.
